Markets:

Overview

News

Currencies

International

Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

33.81 -0.59 (-1.73%)

Streaming Delayed Price Updated: 10:32 AM EDT, Mar 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Top movers in Monday's after hours session ↗

March 17, 2025

As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 17, 2025

Via Benzinga

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

March 17, 2025

From Harrow, Inc.

Via Business Wire

Earnings Scheduled For November 13, 2024 ↗

November 13, 2024

Via Benzinga

Earnings Outlook For Harrow ↗

November 12, 2024

Via Benzinga

The Analyst Landscape: 4 Takes On Harrow ↗

October 04, 2024

Via Benzinga

Harrow Launches VEVYE® Access for All

March 17, 2025

From Harrow, Inc.

Via Business Wire

Earnings Scheduled For March 17, 2025 ↗

March 17, 2025

Via Benzinga

Harrow Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

March 17, 2025

Via Benzinga

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

March 11, 2025

From Harrow, Inc.

Via Business Wire

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

March 03, 2025

From Harrow, Inc.

Via Business Wire

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

February 06, 2025

Via Benzinga

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

January 27, 2025

From Harrow, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 14, 2025

Via Benzinga

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

January 07, 2025

From Harrow, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 29, 2024

Via Benzinga

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

November 21, 2024

From Harrow, Inc.

Via Business Wire

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

November 20, 2024

From Melt Pharmaceuticals, Inc.

Via Business Wire

Harrow Announces Participation in Upcoming Investor Conferences

November 15, 2024

From Harrow, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 14, 2024

Via Benzinga

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

November 14, 2024

Via Benzinga

Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

November 14, 2024

Via Benzinga

Harrow Announces Third Quarter 2024 Financial Results

November 13, 2024

From Harrow, Inc.

Via Business Wire

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

November 13, 2024

From Harrow, Inc.

Via Business Wire

Harrow Announces Market Access Wins for VEVYE®

November 12, 2024

From Harrow, Inc.

Via Business Wire

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products

November 07, 2024

From Harrow, Inc.

Via Business Wire

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

October 31, 2024

From Harrow, Inc.

Via Business Wire

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

October 10, 2024

From Harrow, Inc.

Via Business Wire

Harrow Relaunches TRIESENCE®

October 03, 2024

From Harrow, Inc.

Via Business Wire

Harrow Announces Nashville Expansion

September 25, 2024

From Harrow, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.